ALLO Allogene Therapeutics Inc.

+0.85  (+3%)
Previous Close 28.27
Open 28.56
Price To Book 5.19
Market Cap 3539224998
Shares 121,539,320
Volume 422,862
Short Ratio
Av. Daily Volume 494,207

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 update at ASH December 3, 2018 noted 86% CR/CRi.
Acute lymphoblastic leukemia (ALL)
Phase 1 update 2019.
Refractory B-cell Acute Lymphoblastic Leukaemia
Phase 1/2 trial to be initiated in 2019.
Multiple myeloma
Phase 1 initial data due 1H 2020.
Non-Hodgkin lymphoma (NHL)

Latest News

  1. Allogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call Transcript
  2. Allogene Therapeutics: 1Q Earnings Snapshot
  3. Allogene Therapeutics Reports First Quarter 2019 Financial Results
  4. 2 Big Biotech Stock Upgrades: Can They Reach These Targets?
  5. Allogene Therapeutics Announces Expansion of Scientific Advisory Board
  6. Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
  7. Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
  8. Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
  9. Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
  10. All You Need To Know About Allogene Therapeutics, Inc.’s (NASDAQ:ALLO) Financial Health
  11. Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  12. Allogene Therapeutics, Inc. to Host Earnings Call
  13. Meet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay space
  14. Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
  15. 4 Disruptive Healthcare Stocks You've Never Heard Of
  16. Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
  17. What's next for this slow-moving Peninsula biotech IPO?
  18. Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
  19. KPMG's former S.F. head Debbie Messemer lands on leading fintech's board
  20. East Bay accounting firm’s new leader says improv upped his presentation skills